Bone formation at rhBMP-2-coated titanium implants in the rat ectopic model

被引:80
作者
Hall, Jan
Sorensen, Rachel G.
Wozney, John M.
Wikesjoe, Ulf M. E.
机构
[1] Med Coll Georgia, Sch Dent, Lab Appl Periodont & Craniofacial Regenerat, Dept Periodont, Augusta, GA 30912 USA
[2] Med Coll Georgia, Sch Dent, Lab Appl Periodont & Craniofacial Regenerat, Dept Oral Biol & Maxillofacial Pathol, Augusta, GA 30912 USA
[3] Nobel Biocare AB, Res & Dev, Gothenburg, Sweden
[4] Wyeth Ayerst Res, Womens Hlth & Musculoskeletal Biol, Cambridge, MA USA
关键词
bone; I-125 binding and release; rat ectopic model; rhBMP-2; tissue engineering; titanium implants; titanium porous oxide;
D O I
10.1111/j.1600-051X.2007.01064.x
中图分类号
R78 [口腔科学];
学科分类号
1003 [口腔医学];
摘要
Background: The objective of this study was to evaluate local bone formation at titanium porous oxide (TPO) implant surfaces adsorbed with recombinant human bone morphogenetic protein-2 (rhBMP-2). Methods: In vitro studies were used to estimate the kinetics of I-125-labeled rhBMP-2 released from TPO surfaces with narrow (N) or open (O) pores. Machined/turned titanium (MT) surfaces served as control. The rat ectopic model was used to assess local bone formation. Briefly, TPO-N, TPO-O, and MT disc implants adsorbed with 5, 10, or 20 mu g rhBMP-2, respectively, were implanted subcutaneously into the ventral thoracic region in 5-week-old male Long Evans rats. The animals were euthanized at day 14 postsurgery when implants with surrounding tissues were removed, radiographed, and gross observations recorded. The specimens were processed for histologic evaluation using conventional cut-and-grind techniques. TPO implants without rhBMP-2 included in a preliminary evaluation revealed no evidence of bone formation, tissue encapsulation, or vascularity, thus such controls were not further used. Results: TPO and MT implant surfaces adsorbed with 5 mu g rhBMP-2 retained 2.3-5.4% rhBMP-2 following immersion and rinse in buffer, and 1.1-2.2% rhBMP-2 following repeated immersions and rinses over 27 days. TPO implants retained the most rhBMP-2 and MT implants retained the least. Explants revealed increased hard tissue formation, tissue encapsulation, and vascularity at TPO compared with MT implants. Radiographic observations were consistent with the explant observations. The histologic analysis showed greater amounts of bone formation, osteoblastic cells, osteoid, marrow, tissue encapsulation, vascularity, and bone voids for implants adsorbed with 10 and 20 mu g rhBMP-2, and for TPO implants at the 5-mu g rhBMP-2 dose. The histometric analysis revealed significantly greater bone formation at TPO-O than at MT implants at the 5-mu g rhBMP-2 dose. All surfaces showed significant bone formation at the 10- and 20-mu g dose. Conclusions: rhBMP-2 adsorbed onto TPO implant surfaces executes an osteoinductive effect including bone contacting the implant surface. This effect is surface- and dose-dependent; the TPO-O surface yielding the most bone at the low discriminating rhBMP-2 dose.
引用
收藏
页码:444 / 451
页数:8
相关论文
共 19 条
[1]
Cole BJ, 1997, CLIN ORTHOP RELAT R, P219
[2]
A METHOD FOR THE STUDY OF UNDECALCIFIED BONES AND TEETH WITH ATTACHED SOFT-TISSUES - THE SAGE-SCHLIFF (SAWING AND GRINDING) TECHNIQUE [J].
DONATH, K ;
BREUNER, G .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1982, 11 (04) :318-326
[3]
Esenwein SA, 2001, CHIRURG, V72, P1360, DOI 10.1007/s001040170043
[4]
Composites of bone morphogenetic protein (BMP) and type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics [J].
Gao, T ;
Lindoholm, TS ;
Marttinen, A ;
Urist, MR .
INTERNATIONAL ORTHOPAEDICS, 1996, 20 (05) :321-325
[5]
Hall J., 2000, APPL OSSEOINT RES, V1, P5
[6]
Hanisch O, 1997, INT J ORAL MAX IMPL, V12, P604
[7]
Ectopic bone formation by composites of BMP and metal implants in rats [J].
Herr, G ;
Hartwig, CH ;
Boll, C ;
Kusswetter, W .
ACTA ORTHOPAEDICA SCANDINAVICA, 1996, 67 (06) :606-610
[8]
Keller J C, 1998, Implant Dent, V7, P331, DOI 10.1097/00008505-199807040-00012
[9]
Kuboki Y, 1998, J BIOMED MATER RES, V39, P190, DOI 10.1002/(SICI)1097-4636(199802)39:2<190::AID-JBM4>3.0.CO
[10]
2-K